证券日报网讯1月28日，中源协和（600645）在互动平台回答投资者提问时表示，VUM03注射液是为满 足临床局部使用需求而开发的通用现货型细胞制剂，于2025年3月获批IND，用于治疗非活动性/轻度活 动性克罗恩病复杂性肛瘘。后续如有其它申报项目，公司将依据信息披露规则要求及时披露。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：前期，北科生物干细胞治疗Ⅱ型糖尿病项目在海南博 鳌获批先行先试治疗，请问贵公司持有多少北科生物股权？北科生物近期是否有申请lPO？ 中源协和（600645.SH）1月28日在投资者互动平台表示，尊敬的投资者，您好。北科生物为公司参股 企业，公司持有其11.05%股份，是其众多股东之一，其具备自主经营能力，您可关注其官网等官方平 台发布信息。 ...

本期内容提要：中船集团知乎号获评2025年度影响力政务号；广船国际两船接连完工交付；中船资管 （北京）公司召开2026年度工作会暨党建工作会；中船风帆举办1月职工集体生日会；外高桥造船喜迎 今冬初雪。 | 来 源：中船集团新闻宣传中心/中国船舶报社 | 一 审：曹山泉 | 二 审：项 丽 | 三 审：甘丰录 | 责 编：方 浩/王润超 ...

Core Viewpoint - The company, Zhongyuan Qihhe, has provided insights into its subsidiary OriGene Technologies, Inc. (OTI), highlighting its primary operations in the United States and a smaller presence in Germany [2] Group 1: Company Operations - OTI's main operational base is in the United States, focusing on the sale of research reagents [2] - The subsidiary in Germany contributes a minor portion to the overall revenue of the company [2]

Group 1 - The core point of the article is that Zhongyuan Qihhe (600645.SH) has a subsidiary, OriGene Technologies, Inc. (OTI), which primarily operates in the United States and has established a subsidiary in Germany [2] - OTI's overseas sales of research reagents are mainly focused on the U.S. market, while the German subsidiary contributes a relatively small proportion to the company's overall revenue [2]

Group 1 - The core viewpoint of the news is that Zhongyuan Xiehe's stock has shown a positive trend with a 10.16% increase year-to-date and a market capitalization of 12.99 billion yuan as of January 12 [1] - The company operates in the medical and biological industry, specifically in the field of medical devices and in vitro diagnostics, with a revenue composition primarily from testing reagents (58.46%) and cell detection preparation and storage (26.49%) [1][2] - As of September 30, 2025, Zhongyuan Xiehe reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] Group 2 - The company has not distributed any dividends in the last three years, with a total payout of 37.54 million yuan since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased by 4.06% to 34,700, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2][3] - Major shareholders include Hong Kong Central Clearing Limited, which holds 15.25 million shares, an increase of 902,300 shares compared to the previous period [3]

Group 1 - The core viewpoint of the news is that Zhongyuan Qihua's stock has shown a slight increase of 2.02% recently, with a current trading price of 25.71 yuan per share and a total market capitalization of 12.031 billion yuan [1] - As of September 30, 2025, Zhongyuan Qihua reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] - The company's main business revenue composition includes 58.46% from testing reagents, 26.49% from cell detection preparation and storage, 11.86% from research reagents, 2.40% from genetic testing, and 0.79% from other sources [1] Group 2 - Zhongyuan Qihua operates in the medical biology sector, specifically in medical devices and in vitro diagnostics, with concepts including stem cells, assisted reproduction, biomedicine, cancer treatment, and innovative drugs [2] - The number of shareholders for Zhongyuan Qihua increased by 4.06% to 34,700 as of September 30, 2025, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2] - The company has not distributed any dividends in the last three years, with a total payout of 37.5405 million yuan since its A-share listing [3]

Group 1 - The company has completed all dosing for the Phase I clinical trial of VUM02 for the treatment of idiopathic pulmonary fibrosis (IPF) [2] - The company is currently organizing clinical safety and efficacy data following the completion of the Phase I trial [2] - Future updates regarding the clinical trial progress will be provided through company announcements and regular reports [2]

证券代码：600645 证券简称：中源协和 公告编号：2025-058 中源协和细胞基因工程股份有限公司 关于使用暂时闲置募集资金进行现金管理的进展公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）投资目的 为提高资金使用效率，在不影响募集资金投资项目建设和公司正常经营的情 况下，公司拟使用部分闲置募集资金进行现金管理，可以增加资金收益，为公司 重要内容提示： ●现金管理受托方：华夏银行股份有限公司上海分行 ●现金管理产品名称：人民币单位结构性存款 2511201 ●现金管理金额：1.2 亿元 ●现金管理期限：92 天 ●履行的审议程序：公司于 2025 年 12 月 25 日召开十一届二十四次临时董 事会会议，审议通过了《关于使用暂时闲置的募集资金进行现金管理及自有资金 进行委托理财的议案》。在不影响募集资金投资项目建设和公司正常经营的情况 下，同意公司使用不超过人民币 1.2 亿元的闲置募集资金进行现金管理，自公司 董事会审议通过之日起 12 个月内有效，在审批期限与授权额度内，资金可循环 滚动使用。 ●特别风 ...

Group 1 - The company held its 24th temporary board meeting on December 25, 2025, where several resolutions were passed unanimously by the board members [1][2][4] - The company approved a proposal to postpone the investment project related to the development of tumor marker diagnostic reagents, extending the timeline to December 2026 [35][41] - The company appointed Mr. Zhang Yu as the co-president to enhance operational management efficiency in response to market challenges [2][9] - The company appointed Mr. Li Xu as the secretary of the board, ensuring compliance with relevant laws and regulations [5][10] Group 2 - The company plans to use up to RMB 1.2 billion of temporarily idle raised funds for cash management and up to RMB 600 million of idle self-owned funds for entrusted wealth management [22][24] - The company has a balance of RMB 159.87 million in raised funds as of December 15, 2025, with some funds temporarily idle due to project timelines [24][36] - The company will invest in low-risk, liquid principal-protected products and ensure that these investments do not affect the normal operations of the company [25][32] Group 3 - The company signed a termination agreement with the University of Chinese Academy of Sciences regarding the "Zhongyuan Xiehe Life Medicine Award," ceasing further donations after a total of RMB 7.8 million was contributed [11][12][19] - The termination of the donation agreement will not significantly impact the company's operations or financial status, as it seeks new partners for the award [19][41]